Derek Chalmers - Cara Therapeutic President CEO, Director
| CARA Stock | USD 0.67 0 0.30% |
CEO
Dr. Derek Chalmers, Ph.D. serves as a President, Chief Executive Officer and a Director at Cara Therapeutics, Inc. Dr. Chalmers has over 25 years experience in the biotechnology industry with increasing levels of corporate and business responsibilities. Prior to founding Cara, Dr. Chalmers cofounded Arena Pharmaceuticals, Inc., a drug discovery and development company, and served as its Vice President and Executive Director from June 1997 until May 2004. Dr. Chalmers holds a D.Sc. and Ph.D. in Pharmacology from the University of Glasgow
| Age | 54 |
| Address | 400 Atlantic Street, Stamford, CT, United States, 06901 |
| Phone | 203 406 3700 |
| Web | https://www.caratherapeutics.com |
Cara Therapeutic Management Efficiency
The company has return on total asset (ROA) of (0.493) % which means that it has lost $0.493 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.098) %, meaning that it created substantial loss on money invested by shareholders. Cara Therapeutic's management efficiency ratios could be used to measure how well Cara Therapeutic manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -0.89. The current year's Return On Capital Employed is expected to grow to -1.15. At present, Cara Therapeutic's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Debt To Assets is expected to grow to 0.31, whereas Non Current Assets Total are forecasted to decline to about 9.2 M.Similar Executives
| Found 1 records | CEO Age | ||
| Yuval Cohen | Corbus Pharmaceuticals Holding | 49 | |
Management Performance
| Return On Equity | -1.1 | ||||
| Return On Asset | -0.49 |
Cara Therapeutic Leadership Team
Elected by the shareholders, the Cara Therapeutic's board of directors comprises two types of representatives: Cara Therapeutic inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cara. The board's role is to monitor Cara Therapeutic's management team and ensure that shareholders' interests are well served. Cara Therapeutic's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cara Therapeutic's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Harrison Bains, Director | ||
| Joana Goncalves, Chief Medical Officer | ||
| Derek Chalmers, President CEO, Director | ||
| Mani Mohindru, CFO, Chief Strategy Officer | ||
| Christopher Posner, CEO President | ||
| Michael Lewis, Chief Scientific Officer | ||
| Joana MD, Chief Officer | ||
| Joseph Stauffer, Chief Medical Officer | ||
| Frdrique Menzaghi, Chief RD | ||
| Jeffrey Ives, Director | ||
| Dean Slagel, Independent Director | ||
| Scott Terrillion, Chief Compliance Officer, General Counsel, Secretary | ||
| Beth Weinberg, VP QA | ||
| Eric Vandal, Senior Commercial | ||
| Josef Schoell, CFO | ||
| Martin Vogelbaum, Independent Director | ||
| Iris Francesconi, Chief Relations | ||
| Frederique Menzaghi, VP of RandD | ||
| Dr DSc, CoFounder Advisor | ||
| Ryan Maynard, Chief Officer | ||
| Matthew Murphy, Manager Relations | ||
| Beth RPh, Senior QA |
Cara Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cara Therapeutic a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.1 | ||||
| Return On Asset | -0.49 | ||||
| Operating Margin | (10.85) % | ||||
| Current Valuation | (18.94 M) | ||||
| Shares Outstanding | 54.67 M | ||||
| Shares Owned By Insiders | 14.58 % | ||||
| Shares Owned By Institutions | 45.48 % | ||||
| Number Of Shares Shorted | 2.58 M | ||||
| Price To Earning | 62.54 X | ||||
| Price To Book | 0.73 X |
Pair Trading with Cara Therapeutic
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cara Therapeutic position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cara Therapeutic will appreciate offsetting losses from the drop in the long position's value.Moving together with Cara Stock
| 0.86 | VKTX | Viking Therapeutics Potential Growth | PairCorr |
| 0.78 | ELEV | Elevation Oncology Earnings Call This Week | PairCorr |
| 0.69 | ENVB | Enveric Biosciences Financial Report 20th of May 2024 | PairCorr |
Moving against Cara Stock
| 0.48 | ZURA | Zura Bio Limited Financial Report 10th of May 2024 | PairCorr |
The ability to find closely correlated positions to Cara Therapeutic could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cara Therapeutic when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cara Therapeutic - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cara Therapeutic to buy it.
The correlation of Cara Therapeutic is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cara Therapeutic moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cara Therapeutic moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cara Therapeutic can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cara Therapeutic. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Cara Stock refer to our How to Trade Cara Stock guide.You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Complementary Tools for Cara Stock analysis
When running Cara Therapeutic's price analysis, check to measure Cara Therapeutic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cara Therapeutic is operating at the current time. Most of Cara Therapeutic's value examination focuses on studying past and present price action to predict the probability of Cara Therapeutic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cara Therapeutic's price. Additionally, you may evaluate how the addition of Cara Therapeutic to your portfolios can decrease your overall portfolio volatility.
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |
Is Cara Therapeutic's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cara Therapeutic. If investors know Cara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cara Therapeutic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.19) | Revenue Per Share 0.387 | Quarterly Revenue Growth (0.08) | Return On Assets (0.49) | Return On Equity (1.10) |
The market value of Cara Therapeutic is measured differently than its book value, which is the value of Cara that is recorded on the company's balance sheet. Investors also form their own opinion of Cara Therapeutic's value that differs from its market value or its book value, called intrinsic value, which is Cara Therapeutic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cara Therapeutic's market value can be influenced by many factors that don't directly affect Cara Therapeutic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cara Therapeutic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cara Therapeutic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cara Therapeutic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.